Cellectis ADR (CLLS) Straddle

Trading a CLLS straddle lets you take a pure volatility position on Cellectis ADR without committing to a direction. Cellectis ADR's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate CLLS straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on CLLS profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Cellectis ADR stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the CLLS straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the CLLS straddle is the cleanest expression of that view. Our scanner prices every CLLS straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a CLLS straddle into a catalyst or short a CLLS straddle to harvest decay, the options straddle setups that matter are all in one place.